CL2017000498A1 - A highly active phosphorylated human n-acetylgalactosamine-6-sulfatase (galns) formulation (divisional application 219-2013) - Google Patents

A highly active phosphorylated human n-acetylgalactosamine-6-sulfatase (galns) formulation (divisional application 219-2013)

Info

Publication number
CL2017000498A1
CL2017000498A1 CL2017000498A CL2017000498A CL2017000498A1 CL 2017000498 A1 CL2017000498 A1 CL 2017000498A1 CL 2017000498 A CL2017000498 A CL 2017000498A CL 2017000498 A CL2017000498 A CL 2017000498A CL 2017000498 A1 CL2017000498 A1 CL 2017000498A1
Authority
CL
Chile
Prior art keywords
galns
formulation
sulfatase
acetylgalactosamine
divisional application
Prior art date
Application number
CL2017000498A
Other languages
Spanish (es)
Inventor
Vish Koppaka
Michel Claude Vellard
Kidisti Araya
Augustus O Okhamafe
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of CL2017000498A1 publication Critical patent/CL2017000498A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>UNA FORMULACIÓN QUE INCLUYE DICHA ENZIMA (GALNS) ÚTIL PARA EL DIAGNÓSTICO, PROFILAXIS O TRATAMIENTO DE ENFERMEDADES Y CONDICIONES, CAUSADAS POR ALMACENAMIENTO LISOSOMAL O ASOCIADAS CON UNA DEFICIENCIA EN LA ENZIMA GALNS, POR EJEMPLO, LA MUCOPOLISACARIDOSIS IVa (MPS IVa O SÍNDROME DE MORQUIO A).</p><p> A FORMULATION THAT INCLUDES SUCH ENZYME (GALNS) USEFUL FOR THE DIAGNOSIS, PROFILAXIS OR TREATMENT OF DISEASES AND CONDITIONS, CAUSED BY LISOSOMAL STORAGE OR ASSOCIATED WITH A DEFICIENCY IN THE GALNS ENZYME, THROUGH THE IV EXAMPLE DE MORQUIO A). </p>

CL2017000498A 2010-07-22 2017-03-02 A highly active phosphorylated human n-acetylgalactosamine-6-sulfatase (galns) formulation (divisional application 219-2013) CL2017000498A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36671410P 2010-07-22 2010-07-22

Publications (1)

Publication Number Publication Date
CL2017000498A1 true CL2017000498A1 (en) 2017-11-24

Family

ID=44543776

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013000219A CL2013000219A1 (en) 2010-07-22 2013-01-22 Method for purification of a highly phosphorylated active human n-acetylgalactosamine-6-sulfatase (galns); purified composition comprising galns; method for the prevention of dephosphorylation of a galns enzyme.
CL2017000498A CL2017000498A1 (en) 2010-07-22 2017-03-02 A highly active phosphorylated human n-acetylgalactosamine-6-sulfatase (galns) formulation (divisional application 219-2013)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2013000219A CL2013000219A1 (en) 2010-07-22 2013-01-22 Method for purification of a highly phosphorylated active human n-acetylgalactosamine-6-sulfatase (galns); purified composition comprising galns; method for the prevention of dephosphorylation of a galns enzyme.

Country Status (28)

Country Link
US (3) US8765437B2 (en)
EP (1) EP2595650B1 (en)
JP (2) JP6030553B2 (en)
KR (2) KR101598897B1 (en)
CN (1) CN103037895B (en)
AR (2) AR082319A1 (en)
AU (1) AU2011280937B2 (en)
BR (1) BR112013001558B1 (en)
CA (2) CA3146151A1 (en)
CL (2) CL2013000219A1 (en)
CY (1) CY1118934T1 (en)
DK (1) DK2595650T3 (en)
ES (1) ES2616263T3 (en)
HR (1) HRP20170245T1 (en)
HU (1) HUE033163T2 (en)
IL (2) IL224125B (en)
LT (1) LT2595650T (en)
MX (1) MX341838B (en)
PE (3) PE20171798A1 (en)
PL (1) PL2595650T3 (en)
PT (1) PT2595650T (en)
RS (1) RS55669B1 (en)
RU (1) RU2607376C2 (en)
SG (1) SG187580A1 (en)
SI (1) SI2595650T1 (en)
SM (2) SMT201700106T1 (en)
WO (1) WO2012012718A2 (en)
ZA (1) ZA201300286B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711590C (en) * 2008-01-18 2021-03-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
US20130202633A1 (en) * 2012-02-07 2013-08-08 Saint Louis University, A Non-Profit Organization Determination of immunogenic peptides in lysosomal enzymes and induction of oral tolerance
KR101380740B1 (en) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 Purification of iduronate-2-sulfatase
US11529397B2 (en) 2018-01-22 2022-12-20 Saint Louis University Method of treating mucopolysaccharidosis type IVA
DK2968494T3 (en) * 2013-03-13 2019-03-04 Seattle Genetics Inc ACTIVATED CARBON FILTERING FOR CLEANING BENZODIAZEPINE ADCs
JP2016518113A (en) * 2013-03-13 2016-06-23 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Method for characterization of lysosomal enzymes
CN115120746A (en) 2013-05-15 2022-09-30 明尼苏达大学董事会 Adeno-associated virus-mediated gene transfer to the central nervous system
WO2014201220A1 (en) * 2013-06-12 2014-12-18 The Board Of Trustees Of The University Of Illinois Methods for detecting prostate cancer
US9910041B2 (en) 2013-07-12 2018-03-06 Emd Millipore Corporation Method of determining virus removal from a sample containing a target protein using activated carbon
EP3166626B1 (en) * 2014-07-11 2021-04-28 Biostrategies LC Materials and methods for treating disorders associated with sulfatase enzymes
US10472615B2 (en) 2016-01-21 2019-11-12 Saint Louis University Reduced immunogenic proteins for lysosomal storage disorders
JP2019515677A (en) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー Antibody conjugates and methods of making and using the same
EP3676375A4 (en) * 2017-08-31 2021-04-07 Green Cross Corporation METHOD OF PURIFYING A SULFATASE PROTEIN
MX2020012911A (en) * 2018-05-30 2021-02-26 Esteve Pharmaceuticals Sa Adenoassociated virus vectors for the treatment of mucopolysaccharidoses type iv a.
RU2763990C2 (en) * 2020-02-19 2022-01-12 Акционерное общество "ГЕНЕРИУМ" Cell that produces active protein aryl sulfatase b with high efficiency, and method for obtaining this cell
US20230193205A1 (en) * 2020-04-19 2023-06-22 Figene, Llc Gene modified fibroblasts for therapeutic applications
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
TW202403043A (en) * 2022-03-18 2024-01-16 美商健臻公司 Pharmaceutical recombinant human acid sphingomyelinase compositions and methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
JPS62122588A (en) 1985-11-22 1987-06-03 Taiyo Fishery Co Ltd Production of pure chondroitinase
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
PT101031B (en) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
RU2195492C2 (en) * 2000-09-04 2002-12-27 Институт физиологии Коми научного центра Уральского отделения РАН Method of pectolytic enzyme preparation preparing
DK1395669T3 (en) 2001-01-26 2009-11-16 Selexis Sa Matrix binding regions and methods for using them
US7332304B2 (en) * 2002-07-01 2008-02-19 Arkion Life Sciences Llc Process and materials for production of glucosamine and N-acetylglucosamine
CA2515708A1 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
JP2007277094A (en) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst Modified tick major allergen-containing pharmaceutical composition
EP1836316A4 (en) * 2004-12-22 2009-07-22 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
AU2007240732B2 (en) * 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
US20080231439A1 (en) 2007-03-22 2008-09-25 Inventec Corporation Activity Detection Circuit for a Storage Device
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
CA2711590C (en) * 2008-01-18 2021-03-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
EP2595650B1 (en) 2016-11-16
ZA201300286B (en) 2014-03-26
BR112013001558A2 (en) 2020-08-04
BR112013001558B1 (en) 2022-08-16
CA3146151A1 (en) 2012-01-26
PE20171799A1 (en) 2017-12-28
JP2013532986A (en) 2013-08-22
US8940513B2 (en) 2015-01-27
RS55669B1 (en) 2017-06-30
US20160186149A1 (en) 2016-06-30
KR20150038715A (en) 2015-04-08
CA2805673A1 (en) 2012-01-26
US20120189605A1 (en) 2012-07-26
EP2595650A2 (en) 2013-05-29
HRP20170245T1 (en) 2017-04-21
ES2616263T3 (en) 2017-06-12
IL224125B (en) 2019-02-28
KR101949906B1 (en) 2019-04-22
DK2595650T3 (en) 2017-02-27
PL2595650T3 (en) 2017-06-30
CL2013000219A1 (en) 2014-07-11
WO2012012718A2 (en) 2012-01-26
US20140341878A1 (en) 2014-11-20
SG187580A1 (en) 2013-03-28
SMT201700106T1 (en) 2017-03-08
AR119552A2 (en) 2021-12-29
AU2011280937B2 (en) 2016-06-09
SMT201700106B (en) 2017-03-08
KR20130105605A (en) 2013-09-25
IL260282A (en) 2018-07-31
IL260282B (en) 2020-05-31
JP6030553B2 (en) 2016-11-24
KR101598897B1 (en) 2016-03-03
SI2595650T1 (en) 2017-04-26
MX341838B (en) 2016-09-05
CN103037895A (en) 2013-04-10
HUE033163T2 (en) 2017-11-28
AU2011280937A1 (en) 2013-01-31
PT2595650T (en) 2017-02-22
WO2012012718A3 (en) 2012-04-05
US9567572B2 (en) 2017-02-14
AR082319A1 (en) 2012-11-28
LT2595650T (en) 2017-03-10
CY1118934T1 (en) 2018-01-10
CA2805673C (en) 2022-04-05
RU2607376C2 (en) 2017-01-10
RU2013107765A (en) 2014-08-27
PE20131140A1 (en) 2013-10-17
PE20171798A1 (en) 2017-12-28
US8765437B2 (en) 2014-07-01
CN103037895B (en) 2016-11-09
MX2013000908A (en) 2013-07-05
JP2016178950A (en) 2016-10-13

Similar Documents

Publication Publication Date Title
CL2017000498A1 (en) A highly active phosphorylated human n-acetylgalactosamine-6-sulfatase (galns) formulation (divisional application 219-2013)
MX2010007846A (en) MANUFACTURE OF HUMAN LISOSOMAL SULFATASE ENZYMES HIGHLY PHOSPHORILED, ACTIVE AND USES OF THE SAME.
ES2544967T3 (en) Formulation and method for the prevention and treatment of bone metastases or other bone diseases
CL2020000468A1 (en) Use of a stable formulation comprising a replacement enzyme for the lysosomal enzyme (divisional application 201801220)
MX2019000547A (en) LIQUID AND LYOPHILIZED, STABILIZED FORMULATIONS OF ADAMTS13.
MX2020002867A (en) GLUCOSYLCERAMIDE SYNTHASE INHIBITORS.
CL2016001553A1 (en) Media for cell culture
BR112014031874A2 (en) method for preparing high concentration stem cells
BRPI0906549A2 (en) Medical bandages with valves and kits containing them.
ECSP13012978A (en) GLUCOSILCERAMIDE SINTASA INHIBITORS
CO6571886A2 (en) Pcsk9 antagonists
BR112015013349A2 (en) trieptanoin for the treatment of glucose transporter deficiency 1
CL2010000829A1 (en) Method for treating plants that comprises applying to the plants a liquid composition containing between 0.3 and 300 milligrams of one or more cyclopropenes per liter of said composition.
BR112012007798A2 (en) stable microcapsules and composition for topical application and method for preparing microcapsules
UA113188C2 (en) METHOD OF PREPARATION OF HYDROGEL WITH USE OF LIPASE ENZYMES
BR112012019920A2 (en) pyridazine derivatives useful as cannabinoid-2 agonists.
BRPI0700133A (en) pharmaceutical composition comprising tramadol and ketoprofen in combination
CL2010001594A1 (en) Use of nifurtimox to prepare a medicine useful in the treatment of diseases caused by trichomonadide.
WO2011103458A3 (en) Compositions and methods for using and identifying antimicrobial agents
MX2021008091A (en) Composition comprising arthropods and astigmatid mite eggs.
PH12014501307A1 (en) Liquid activation system
ITMI20052515A1 (en) PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF OSTEOARTRITE
RU2009136584A (en) VEGETABLE ANThelmintic
AR118157A2 (en) A RECOMBINANT HUMAN N-ACETYLGALACTOSAMINE-6-SULFATASE (GALNS) ENZYME, COMPOSITION AND ITS USES
MX2016010719A (en) SUBSTRATE CLEARANCE TESTS FOR LISOSOMAL ENZYMES.